TCTMD

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

WASHINGTON, DC—Two-year results from the ABSORB III study presented today at the American College of Cardiology 2017 Scientific Session show that the Absorb GT1 bioresorbable vascular scaffold (BVS, ...
Healio

ABSORB III 2-year results suggest optimal techniques may be key

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — At 2 years, the cumulative rate of target ...
Medscape

Negative Data Piling Up on Absorb Bioresorbable Scaffold

AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...
Healio

ABSORB II: Bioresorbable scaffold outcomes comparable to DES at 1 year

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The Absorb bioresorbable scaffold demonstrated overall clinical outcomes comparable to those of the ...